Cannabidiol Effects on Cortical Excitability: Evidence from a Randomized, Double-Blind, Placebo-Controlled Study
Clinical Takeaway
In this controlled trial, neither a low nor a high single dose of CBD directly altered cortical excitability or produced measurable sedation in healthy adults, suggesting CBD may not have meaningful intrinsic anti-seizure activity on its own. The established clinical benefit of CBD in Dravet syndrome and Lennox-Gastaut syndrome likely depends on its pharmacokinetic interaction with clobazam rather than a direct brain effect. Clinicians should keep this distinction in mind when counseling patients about CBD use outside of a supervised, combination treatment protocol.
#14 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
What This Study Teaches Us
In healthy volunteers, CBD at doses up to 700 mg did not directly suppress brain electrical activity or produce sedation, despite being FDA-approved for seizure disorders. This raises the possibility that CBD’s anti-seizure benefit may depend on interactions with other medications rather than on intrinsic anti-epileptic properties.
Why This Matters Clinically
Clinicians prescribing CBD for seizures often assume it has direct anti-seizure effects. This study suggests we may need to reconsider the mechanism and rethink how we interpret its role in polypharmacy, especially whether its benefit comes from enhancing other drugs like clobazam rather than from CBD itself.
Study Snapshot
| Study Design | Randomized, double-blind, placebo-controlled 3-way crossover trial |
| Population | 25 healthy males, no seizure disorder, no comorbidities specified |
| Intervention | Single oral doses of 30 mg CBD, 700 mg CBD, or placebo on separate visits |
| Primary Outcome | Cortical excitability measured by transcranial magnetic stimulation combined with EMG and EEG; sedative effects by CNS test battery |
| Key Result | CBD showed no significant effect on TMS-EMG parameters or sedation; minor EEG clusters at 3-5 hours post-dose were not associated with clinical effects |
Where This Paper Deserves Skepticism
This study uses healthy volunteers, not patients with seizure disorders, which limits direct applicability to epilepsy populations where CBD is actually used. The abstract reveals only minor and clinically inconsistent EEG findings without explaining their significance. We don’t know funding source, potential conflicts, or whether single-dose pharmacology in healthy males predicts repeat-dose effects in patients on polypharmacy. The mechanism question deserves more data from actual patient populations on actual seizure outcomes.
Dr. Caplan’s Take
I find this study thought-provoking but preliminary. It challenges us to think more carefully about how CBD actually works in seizure patients, and it’s a useful correction to oversimplified marketing claims about CBD as a direct anticonvulsant. That said, healthy volunteers on single doses are a poor proxy for epilepsy patients on chronic regimens interacting with clobazam and other drugs. The study opens a legitimate question about pharmacokinetic synergy but doesn’t close it. I’d want to see similar mechanistic work in actual seizure populations before revising our clinical understanding.
Clinical Bottom Line
This study suggests CBD may not work as a direct anti-seizure agent in the brain, but rather through interactions with co-medications like clobazam. Don’t use this single healthy-volunteer study to abandon CBD in seizure patients, but do recognize it as a signal that we need better mechanistic science in actual patient populations.
| |
Have thoughts on this? Share it:
